SEC Comment Letter 0000000000-24-012197 to NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258) (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258)
Date: Nov. 1, 2024 · CIK: 0001936258 · Accession: 0000000000-24-012197
AI Filing Summary & Sentiment
File numbers found in text: 001-41562
Letter
November 1, 2024 Ian Somaiya Chief Financial Officer New Amsterdam Pharma Company N.V. Gooimeer 2-35 Naarden The Netherlands 1411 DC Re:New Amsterdam Pharma Company N.V. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 28, 2024 File No. 001-41562 Dear Ian Somaiya: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Brian Rosenzweig
Show Raw Text
November 1, 2024
Ian Somaiya
Chief Financial Officer
New Amsterdam Pharma Company N.V.
Gooimeer 2-35
Naarden
The Netherlands 1411 DC
Re:New Amsterdam Pharma Company N.V.
Form 10-K for the Fiscal Year Ended December 31, 2023
Filed February 28, 2024
File No. 001-41562
Dear Ian Somaiya:
We have completed our review of your filings. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Brian Rosenzweig